According to the Leukemia & Lymphoma Society, acute graft-versus-host disease affects approximately 40-50% of patients receiving allogeneic stem cell transplantation. It occurs when the body's immune system (transplanted along with a donor organ or stem cells) attacks the recipient's tissues. Several clinical trials are ongoing to develop innovative steroid refractory acute graft versus host disease therapeutic drugs for the condition.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing steroid refractory acute graft versus host disease pipeline development activities are covered in this report.
The recommended first-line treatment for aGVHD is systemic steroid therapy, however, approximately 35 to 50% of patients become refractory to steroid therapy. The treatment options are typically based on the severity and stage of GVHD, specific organs affected, and the patient's overall condition. Management of steroid refractory acute GVHD involves a multidisciplinary team approach including hematologists, immunologists, and transplant specialists among others. Since managing the condition effectively is important to improve clinical outcomes of patients undergoing stem cell or organ transplantation, with an estimated 6-month survival of only 40% of patients after disease development, several trials are ongoing. For instance, an open-label phase II study conducted by Incyte Corporation evaluated the safety and efficacy of ruxolitinib in steroids-refractory acute graft-versus-host disease and reported favorable outcomes with a 6-month survival rate of 70%. The increased number of drug clinical trials for steroid-refractory acute graft versus host disease has impacted the pipeline landscape significantly.
Biological: OSSM-001
The objective of the study is to evaluate the safety and feasibility of a single-dose infusion of OSSM-001 to treat steroid refractory acute GVHD. The trial is sponsored by Ossium Health, Inc. and is currently under phase I.
This product will be delivered within 3-5 business days.
Report Coverage
The Steroid Refractory Acute Graft Versus Host Disease Pipeline Report by the publisher gives comprehensive insights into steroid-refractory acute graft versus host disease drugs currently undergoing clinical trials. The report covers various aspects related to the details of each of these drugs under development for the disease. The steroid refractory acute graft versus host disease pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies . It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from steroid refractory acute graft versus host disease.The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing steroid refractory acute graft versus host disease pipeline development activities are covered in this report.
Steroid Refractory Acute Graft Versus Host Disease Drug Pipeline Outlook
Steroids-refractory acute graft-versus-host disease is a severe condition in patients undergoing allogeneic hematopoietic stem cell transplantation. The condition is associated with a high mortality risk and higher nonrelapse mortality at 18 months than patients who responded to steroid treatment.The recommended first-line treatment for aGVHD is systemic steroid therapy, however, approximately 35 to 50% of patients become refractory to steroid therapy. The treatment options are typically based on the severity and stage of GVHD, specific organs affected, and the patient's overall condition. Management of steroid refractory acute GVHD involves a multidisciplinary team approach including hematologists, immunologists, and transplant specialists among others. Since managing the condition effectively is important to improve clinical outcomes of patients undergoing stem cell or organ transplantation, with an estimated 6-month survival of only 40% of patients after disease development, several trials are ongoing. For instance, an open-label phase II study conducted by Incyte Corporation evaluated the safety and efficacy of ruxolitinib in steroids-refractory acute graft-versus-host disease and reported favorable outcomes with a 6-month survival rate of 70%. The increased number of drug clinical trials for steroid-refractory acute graft versus host disease has impacted the pipeline landscape significantly.
Steroid Refractory Acute Graft Versus Host Disease - Drug Pipeline Therapeutic Assessment
This section of the steroid refractory acute graft versus host disease report covers the analysis of steroid refractory acute graft versus host disease emerging drugs based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase.- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The steroid refractory acute graft versus host disease therapeutic assessment covers 50+ drug analyses based on drug classes:
- Monoclonal Antibody
- Peptides
- Small Molecule
By Route of Administration
The steroid refractory acute graft versus host disease clinical assessment covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Steroid Refractory Acute Graft Versus Host Disease - Pipeline Assessment Segmentation, By Phases
The steroid refractory acute graft versus host disease report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for steroid refractory acute graft versus host disease pipeline drugs.Steroid Refractory Acute Graft Versus Host Disease - Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under steroid refractory acute graft versus host disease pipeline analysis include monoclonal antibodies, peptides, and small molecules. Begelomab, (a monoclonal antibody against CD26) is a promising therapy in severe steroid refractory acute graft versus host disease. It is a marker for T cell activation and CD26+ T cells accumulated in inflamed tissues. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for steroid refractory acute graft versus host disease.Steroid Refractory Acute Graft Versus Host Disease Clinical Trials Assessment - Competitive Dynamics
The report for the steroid refractory acute graft versus host disease report insights covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in steroid refractory acute graft versus host disease clinical trials:- ASC Therapeutics
- AltruBio Inc.
- Xenikos
- Novartis Pharmaceuticals
- Ossium Health, Inc.
- ElsaLys Biotech
- AbGenomics B.V Taiwan Branch
- Others
Steroid Refractory Acute Graft Versus Host Disease - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and steroid refractory acute graft versus host disease therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming steroid refractory acute graft versus host disease drug candidates.Drug: Ruxolitinib
The trial is designed to evaluate the efficacy and safety of ruxolitinib with either grade II-IV aGvHD or grade II-IV SR-aGvHD. The trial is sponsored by Novartis Pharmaceuticals and is currently under phase II.Biological: OSSM-001
The objective of the study is to evaluate the safety and feasibility of a single-dose infusion of OSSM-001 to treat steroid refractory acute GVHD. The trial is sponsored by Ossium Health, Inc. and is currently under phase I.
Drug: T-Guard
Xenikos is developing this steroid refractory acute graft versus host disease drug candidate and is currently under phase III. The study is being conducted to compare the safety and efficacy of T-Guard to ruxolitinib in patients with grade III or IV steroid-refractory acute graft-versus-host disease.Reasons To Buy This Report
The Steroid Refractory Acute Graft Versus Host Disease Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for steroid refractory acute graft versus host disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within steroid refractory acute graft versus host disease pipeline insight.Key Questions Answered in the Steroid Refractory Acute Graft Versus Host Disease - Pipeline Assessment Report
- What is the current landscape of steroid refractory acute graft versus host disease pipeline drugs?
- Which companies/institutions are developing steroid refractory acute graft versus host disease emerging drugs?
- How many phase II drugs are currently present in steroid refractory acute graft versus host disease pipeline drugs?
- Which company is leading the steroid refractory acute graft versus host disease pipeline development activities?
- What is the current steroid refractory acute graft versus host disease therapeutic assessment?
- What are the opportunities and challenges present in the steroid refractory acute graft versus host disease drug pipeline landscape?
- Which companies/institutions are involved in steroid refractory acute graft versus host disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in steroid refractory acute graft versus host disease?
- What is the efficacy and safety profile of steroid refractory acute graft versus host disease pipeline drugs?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Steroid Refractory Acute Graft Versus Host Disease
4 Patient Profile: Steroid Refractory Acute Graft Versus Host Disease
5 Steroid Refractory Acute Graft Versus Host Disease: Epidemiology Snapshot
6 Steroid Refractory Acute Graft Versus Host Disease: Market Dynamics
7 Steroid Refractory Acute Graft Versus Host Disease: Key Facts Covered
8 Steroid Refractory Acute Graft Versus Host Disease, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Steroid Refractory Acute Graft Versus Host Disease Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Steroid Refractory Acute Graft Versus Host Disease Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Steroid Refractory Acute Graft Versus Host Disease Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Steroid Refractory Acute Graft Versus Host Disease Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Steroid Refractory Acute Graft Versus Host Disease, Key Drug Pipeline Companies
